An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin.

Trial Profile

An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2016

At a glance

  • Drugs Fostamatinib (Primary) ; Rifampicin
  • Indications Haematological malignancies; Rheumatoid arthritis; Tuberculosis; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jan 2016 Results of this and other two phase I studies published in the Drugs in R and D
    • 21 Jul 2011 Actual end date July 2011 added as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top